Bluebird Bio submits BLA for sickle cell disease gene therapy

bluebird bio has today announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD).